Umoja Biopharma Showcases Innovative Research at SITC Meeting
Umoja Biopharma, Inc., a pioneering company in the field of immunotherapy, is set to unveil its groundbreaking research at the upcoming 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). This prestigious event will be held from November 6 to 10 in Houston.
About Umoja Biopharma
Umoja Biopharma is revolutionizing cancer treatment with its innovative approach to off-the-shelf therapeutics. The company is dedicated to advancing CAR-T cell therapies, which use a patient’s own immune system to combat cancer and autoimmune diseases. Their cutting-edge VivoVec™ gene delivery technology empowers the immune system, making it more effective in fighting diseases.
Poster Presentations at SITC
At the SITC meeting, Umoja will present two significant poster presentations, enriching the scientific discussions with vital insights.
First Presentation Overview
The first poster will showcase preclinical data on UB-VV400, a specially engineered lentiviral vector that generates CD22-directed CAR T cells in vivo without necessitating lymphodepleting chemotherapy. This advancement potentially streamlines the treatment process for patients, enhancing access to effective therapies.
Second Presentation Overview
The second poster highlights the company’s innovative platform that induces cytotoxic lymphocytes (iCIL). This technology aims to promote improved production and longevity of CAR T cells, a crucial factor in the efficacy of immunotherapy.
Poster Presentation Details
Umoja's poster presentation on the UB-VV400 will be led by Dr. Jeffrey Teoh on Friday, November 8, from 9 am to 7 pm CT (Poster Number: 1145). Another insightful presentation by Dr. Dillon Jarrell on Saturday, November 9, from 9 am to 8:30 pm CT (Poster Number: 272) will delve into expanding the capabilities of stem-cell derived lymphocytes.
Collaboration with Seattle Children's Therapeutics
In addition, Umoja's collaboration partner, Seattle Children's Therapeutics, will share their findings on the ENLIGHTen-01 trial of UB-TT170. This presentation will provide insight into a Phase 1 study exploring a unique CAR T-cell therapy for osteosarcoma, showcasing the potential of advanced therapeutic solutions.
Engaging with Umoja Biopharma
Umoja is not just about innovation; it’s about the mission to make groundbreaking therapies accessible to those in need. Their state-of-the-art lentiviral vector manufacturing facility located in Louisville plays a crucial role in achieving this mission. This facility not only supports their internal development but also emphasizes their commitment to expand the reach of immunotherapies for a broader patient base, enhancing overall treatment outcomes.
Looking Ahead in Immunotherapy
The future of immunotherapy is bright with companies like Umoja Biopharma at the forefront. Their relentless pursuit of innovation and improvement in CAR-T therapies sets a hopeful path for patients across the globe, ensuring that more people can benefit from these life-changing treatments.
Frequently Asked Questions
What is Umoja Biopharma's primary focus?
Umoja Biopharma is focused on developing off-the-shelf immunotherapies using advanced CAR-T cell therapies to treat cancer and autoimmune diseases.
When will Umoja present at the SITC Meeting?
Umoja will present its research at the SITC Meeting from November 6 to 10, with specific poster presentations on November 8 and 9.
What are the key topics of Umoja's posters?
The posters will cover preclinical research related to UB-VV400 and a platform for inducing cytotoxic lymphocytes aimed at enhancing CAR T cell efficacy.
Who are Umoja Biopharma's collaboration partners?
Umoja collaborates with Seattle Children's Therapeutics, among other partners, to advance its research and clinical trials.
Where can I learn more about Umoja Biopharma?
You can learn more about Umoja Biopharma and their innovative approaches by visiting their official website and following them on LinkedIn.
